**T-Cell Adhesion in Healthy and Inflamed Skin**

Joshua M. Moreau¹, Victoire Gouirand¹ and Michael D. Rosenblum¹

The diverse populations of tissue-resident and transitory T cells present in the skin share a common functional need to enter, traverse, and interact with their environment. These processes are largely dependent on the regulated expression of adhesion molecules, such as selectins and integrins, which mediate bidirectional interactions between immune cells and skin stroma. Dysregulation and engagement of adhesion pathways contribute to ectopic T-cell activity in tissues, leading to the initiation and/or exacerbation of chronic inflammation. In this paper, we review how the molecular interactions supported by adhesion pathways contribute to T-cell dynamics and function in the skin. A comprehensive understanding of the molecular mechanisms underpinning T-cell adhesion in inflammatory skin disorders will facilitate the development of novel tissue-specific therapeutic strategies.

*JID Innovations* (2021);1:100014 doi:10.1016/j.xjidi.2021.100014

**Overview**

Adhesion is a fundamental process in immune cell function. This is definitively demonstrated by leukocyte adhesion deficiency (LAD) syndrome, a rare genetic disorder caused by defects in a select number of adhesion genes, especially in ITGB2. Without bone marrow transplantation, patients with severe disease are prone to recurrent infections, demonstrate impaired wound healing, and are unlikely to survive beyond 2 years of life (Almarza Novoa et al., 2018). Immune responses in peripheral tissues require adhesion pathways to mediate cell recruitment, tissue immunosurveillance, and intercellular interaction between different cell types. These activities are dependent on a large assemblage of adhesion proteins, including integrins, selectins, and cadherins that mediate cell–cell and cell–extracellular matrix (ECM) interactions. Contact between adhesion molecules and their ligands provides a means for force transmission and signal transduction that enables cellular movement, positioning, and the tight interactions required for immune synapse formation (Basu and Huse, 2017; Cavallaro and Dejana, 2011; Hammer et al., 2019). Adhesive function is directly driven by adhesion proteins but also encompasses the layers of regulatory mechanisms that create cell lineage (i.e., CD4⁺ T cell vs. CD8⁺ T cell), cell state (i.e., quiescence vs. activation), and tissue (i.e., skin vs. colon) specificity.

Mammalian skin contains large populations of tissue-resident and recirculating T cells. These cells protect against infection and also play an important role in maintaining skin barrier integrity and tissue homeostasis. Regulatory T cells (Tregs) interact with epithelial stem cells to facilitate differentiation during hair follicle (HF) cycling (Ali et al., 2017), whereas Tregs, subsets of CD8⁺ T cells, MAIT cells, and γδ T cells contribute to wound repair and re-epithelialization after skin injury (Constantinides et al., 2019; Harrison et al., 2019; Jameson et al., 2002; Nosbaum et al., 2016). In addition, Tregs keep local immune responses in balance by tightly regulating inflammatory signaling (Kalekar and Rosenblum, 2019; Kalekar et al., 2019). Performing these functions in the skin requires adhesion-mediated recruitment, interstitial migration, and cell–cell interaction. In this study, we follow T cells on a journey as they enter and traverse the skin, interact with antigen-presenting cells or malignant cells, and eventually emigrate to draining lymph nodes. We review how the outcome of this journey is determined by the composition of adhesion molecules expressed on various skin T-cell populations and describe how inflammation and immune activation shape adhesive capacity.

Not surprisingly, dysregulation of T cells in the skin is a prominent feature of many skin disorders, and either augmentation or suppression of their activity provides a compelling strategy toward treating human disease (Ho and Kupper, 2019). Given the importance of cellular adhesion in immune cell function, adhesion molecules have long been considered promising therapeutic targets (Ley et al., 2016). Research and clinical efforts in this area have produced several therapies currently approved for the treatment of autoimmune diseases, including multiple sclerosis and Crohn’s disease (Ley et al., 2016). Unfortunately, these successes have yet to be realized for the treatment of skin disorders. To date, Efalizumab, the only adhesion-targeting therapy approved for a skin disease (psoriasis) was withdrawn from clinical use secondary to severe and potentially life-threatening side effects (Pugashetti and Koo, 2009). Nonetheless, rapid progress in understanding the nuances surrounding T-cell adhesion in tissues provides the justification for continued exploration of these pathways as targets for therapeutic manipulation. In this paper, we discuss the attempts to develop therapies modulating T-cell adhesion and examine the opportunities for applying new research findings toward developing treatments for skin disease.

¹Department of Dermatology, University of California San Francisco, San Francisco, California, USA

Correspondence: Michael D. Rosenblum, Department of Dermatology, University of California San Francisco, Medical Sciences Building, Health Sciences West - 1201B, 513 Parnassus Avenue, San Francisco, California 94132, USA. E-mail: Michael.Rosenblum@ucsf.edu

Abbreviations: AD, atopic dermatitis; BM, basement membrane; DC, dendritic cell; DETC, dendritic epidermal γδ T cell; ECM, extracellular matrix; HF, hair follicle; JC, John Cunningham; LAD, leukocyte adhesion deficiency; PMNL, progressive multifocal leukoencephalopathy; Th, T helper; Treg, regulatory T cell; Trm, tissue-resident memory

Received 24 March 2021; accepted 6 April 2021; accepted 30 April 2021; corrected proof published online 29 May 2021

Cite this article as: JID Innovations 2021;1:100014

© 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
A T cell’s guide to skin adhesion

In the absence of inflammatory signals, tissue-resident T cells, including tissue-resident memory (Trm) cells and dendritic epidermal γδ T cells (DETCs) (in mice), continually survey the skin while other subsets circulate between the tissue, draining lymph nodes, and peripheral blood (Brown et al., 2010; Collins et al., 2016; Gebhardt et al., 2011). Despite the significant differences in the ontogeny and transcriptional signature of tissue-resident and recirculating T cells (Szabo et al., 2019), adhesion molecules are a shared molecular requirement for movement into and through the skin. However, differential induction or activation of adhesion pathways contributes to nuances in the functional behaviors of each population. Broadly, there are four phases of T-cell behavior dependent on adhesion: entry into the skin, interstitial migration, interactions with other cells, and egress from the skin (Figure 1). An individual T cell may not be primed to perform each step sequentially, but it will need to express a specific set of molecules to accomplish any given task. In the following sections, we discuss how T cells use adhesion molecules in the context of each process. However, it should be noted that the majority of research in this field to date has focused on proinflammatory T cells (i.e., conventional CD4+ and CD8+ T cells) and that much less is known about how Tregs utilize adhesion and adhesion-associated molecules to regulate their functions in the skin.

A sticky toolkit: regulation of T-cell adhesion. Cellular adhesion is principally driven by several groups of molecules expressed on T cells, including integrins, selectins, cadherins, and Ig superfamily members (Figure 2) (Harjunpää et al., 2019). T cells also express a number of other glycoproteins, such as CD44, that contribute to mediating adhesion (Baaten et al., 2012). Many additional proteins indirectly influence cellular behavior by regulating the ability of expressed adhesion molecules to bind their ligand. For example, most integrins are present on the cell surface in a relatively closed conformational state with a low affinity for ligand binding. TCR engagement or chemokine exposure produces signaling cascades that induce a conformational change in both integrin subunits. This extends the integrin into an active form and substantially increases ligand affinity (Harjunpää et al., 2019). Transformation into an active conformation is dependent on the integrin-binding proteins, talin and kindlin, which mediate force transmission through connections to the cytoskeleton (Harjunpää et al., 2019; Sun et al., 2019). Through these cytoskeletal interactions, integrins and other adhesion molecules impart T cells with mechanosensitivity that is essential for navigating the mechanically dynamic tissue environment of the skin (Biggs et al., 2020; Sun et al., 2019).

Interestingly, additional adaptor proteins modulate talin-integrin interactions leading to cell lineage and cell state-dependent augmentation of adhesion. Recently, we found that the talin-binding C-type lectin, layilin, is preferentially expressed on highly activated CD8+ T cells infiltrating melanoma tumors but is nearly absent on T cells in peripheral blood (Borowsky and Hynes, 1998; Mahuron et al., 2020). Layilin enhances integrin αββ2 (LFA-1) activation and binding to its ligand ICAM-1 to promote antitumor immunity (Mahuron et al., 2020). CD8+ T cells expressing high levels of IL-17 (Tc17 cells) infiltrating psoriatic lesions are also enriched for layilin expression compared with T cells from healthy skin, suggesting that although layilin may protect against cancer, it could contribute to autoimmunity (Liu et al., 2020). Differential regulation of integrin activation was also demonstrated between Tregs and CD4+ T-conventional cells. Whereas most CD4+ T cells are entirely dependent on RIAM to mediate β integrin binding to talin, this protein is dispensable in Tregs. Deletion of RIAM protected mice in a spontaneous colitis model owing to a reduced accumulation of effector T cells in the gut, whereas Treg homing to this tissue was normal (Sun et al., 2021). Lamelllipodin, a RIAM paralog preferentially expressed in Tregs, is able to facilitate integrin–talin binding in these cells (Sun et al., 2021).

The expression pattern of adhesion molecules themselves also has importance in dictating T-cell function. For T cells to gain access to peripheral tissues, they must actively leave circulation, migrate through interstitial spaces, interact with other cells, and eventually return to circulation by lymphatic vessels. Each of these processes is dependent on adhesive interactions between T cells and other cells or between T cells and the extracellular matrix. Expression patterns of adhesion molecules temporally and spatially regulate T-cell dynamics by selectively assisting specific movements. Only those T cells expressing the correct collection of adhesion receptors will be able to traverse the tissue environment. Inflammation controls T-cell access to the tissue by modulating this adhesion molecule signature.
examining T-cell recruitment under inflammatory conditions have implicated CD43 and CD44 as additional E-selectin ligands contributing to skin entry (Ali et al., 2017a; Nacher et al., 2011). Integrin expression is also critical because CD18/CD10 (the β2 subunit of LFA-1) knockout mice exhibited reduced inflammation in allergic contact dermatitis and delayed-type hypersensitivity reactions owing to impaired T-cell accumulation in skin lesions. Notably, Langerhans cell precursors and dendritic cells (DCs) displayed normal migratory behavior (Grabbe et al., 2002). Conversely, mice with a hypomorphic mutation that reduces CD18 levels to 2–16% of wild type spontaneously develop skin lesions mirroring human psoriasis (Bullard et al., 1996). In this context, both CD4+ and CD8+ T cells efficiently enter the skin, and tissue pathology is potentiated by a defective Treg compartment (Kess et al., 2003; Singh et al., 2013; Wang et al., 2008). Reduced CD18 was observed to hinder Treg interaction with DCs, impair their suppressive capability, and promote lineage instability by converting Tregs to IL-17-producing effector T helper (Th17) cells (Singh et al., 2013; Wang et al., 2008). Another integrin important for skin-specific function (although not for entry into the skin) is α4β1. CD103 (the αε subunit of α4β1) is a marker of Trm cells and is widely expressed among T cells in the skin (Hardenberg et al., 2018). α4β1 interacts with E-cadherin and likely has a role in positioning T cells within the tissue by allowing an interaction with the epithelium (discussed in detail in the following section) (Hardenberg et al., 2018). Mice deficient in CD103 develop severe skin lesions at least partially owing to a defective Treg compartment (Braun et al., 2015; Schön et al., 2000). Collectively, these observations begin to define an adhesome signature intrinsically connected to T-cell function in the skin.

**Entry into the skin.** T-cell entry into the skin is initiated by tethering and rolling interactions with blood vessel endothelial cells (Garrood et al., 2006; Schön et al., 2003). CLA and a related glycoprotein, PSLG-1 (CD162), expressed on T cells bind endothelial E- and P-selectin. In addition, CD44 coassociation with integrin α4β1 (VLA-4) has been found to facilitate early binding to the endothelial ligand VCAM-1 (Issekutz and Issekutz, 2002; Nandi et al., 2004; Schön et al., 2003; Siegelman et al., 2000). These relatively low-affinity interactions act to slow down the T cells caught in high-speed blood flow (Garrood et al., 2006; Schön et al., 2003). Some nuance has been reported in the mechanisms utilized by different T-cell subsets to initiate tethering. Th1, Th17, and Tregs were found to use a tether and sling behavior to improve adherence efficiency. These subsets were markedly better at forming these structures than Th2 cells, which directly translated into superior attachment to the vessel wall (Abadier et al., 2017). Similarly, in Th1 and Th17 but not in Th2 cells, TIM-1 binds P-selectin to promote skin entry (Angiari et al., 2014). Interestingly, this may explain why tissue-resident Th2 cells are absent in healthy skin of C57BL/6 mice, whereas Tregs and Th1 cells are readily observed (Nussbaum et al., 2013).

![Figure 2. A diverse set of molecules drive T-cell adhesion.](image-url)
Low-velocity travel along vessel walls stimulates integrin activation leading to firm adhesion primarily through LFA-1/ICAM-1 and VLA-4/VCAM-1 binding (Garrood et al., 2006; Schönh et al., 2003). Firm adhesion fully arrests the T cells and allows cytoskeleton reorganization and cellular polarization to form a leading-edge lamellipodium. Lymphocytes then traverse the endothelium primarily through endothelial cell junctions (Garrood et al., 2006; Sumagin and Sarelius, 2010). Integrins facilitate transendothelial migration through bidirectional signaling that both increases endothelial permissiveness and directly prepares T cells for tissue entry. LFA-1 engagement with ICAM-1 on endothelial cells induces a MAPK signaling cascade that in turn promotes vascular permeability and induces cytokine and chemokine production (Dragoni et al., 2017; Sumagin and Sarelius, 2010). In T cells, LFA-1 ligation during transendothelial migration was recently found to drive the synthesis of intracellular complement C3, which was among the most enriched molecular signature of tissue lymphocytes. Examining the T cells from patients with LAD syndrome, the study authors observed reduced C3 mRNA and impaired effector cytokine production (Kolev et al., 2020). Other integrins besides LFA-1 likely contribute to transendothelial migration because the double deletion of the cytoskeletal effector proteins, VASP and EVL, impaired T-cell trafficking into lipopolysaccharide-treated ear skin owing to defective integrin α4 function. Strikingly, T cells deficient in both VASP and EVL exhibited normal crawling and adhesion under shear flow but defective transendothelial migration (Estin et al., 2017).

Because T-cell entry into tissue is a critical point in their functional capability, the processes of rolling, firm adhesion, and transendothelial migration are highly influenced by inflammatory and pathologic conditions. Such stimuli modify adhesion molecule expression on both T cells and the endothelium to regulate lymphocyte entry into the skin (Capece et al., 2017; DeNucci et al., 2010; Ley and Kansas, 2004; Mahuron et al., 2020). For example, analysis of peripheral blood from both adult and pediatric patients with atopic dermatitis (AD) revealed the expansion of CLA⁺ Th2 cells, consistent with the type-2 inflammatory skew of this disease (Czarnowicki et al., 2015a, 2015b). In ex vivo transendothelial migration experiments, blood-derived T cells from patients with scleroderma exhibited significantly enhanced migratory ability compared with healthy control cells (Stummvoll et al., 2004). In support of these findings, CD4⁺ T cells from patients with scleroderma not only expressed elevated levels of CD11a (the αL subunit of LFA-1) but also reduced the methylation of the CD11a promoter, indicating an epigenetically encoded propensity for increased integrin expression (Wang et al., 2014). These results suggest that in patients with skin disease, circulating T cells are likely ectopically primed for tissue entry.

**Interstitial migration.** After passing through the endothelium, T cells enter into a complex 3–dimensional interstitial space comprising tissue cells, soluble signaling mediators, and the ECM. T cells must integrate cues from this environment to patrol the tissue and position themselves within the skin microarchitecture (Gaylo et al., 2016). Cutaneous tissue is a dynamic and high-force environment that experiences differential levels of mechanical stress across the epidermis and dermis and during tissue renewal (Biggs et al., 2020; Hsu et al., 2018). Notably, injury and inflammation precipitate the remodeling of the ECM, which influence the signals T cells receive through their adhesion receptors (Gaylo et al., 2016; Hsu et al., 2018). Consequently, T-cell motility behaviors (i.e., travel speed and area of immunosurveillance) are directly dictated by the mechanical landscape within the tissue (Gaylo et al., 2016). An abnormal distribution of tissue forces is a feature of several skin disorders (Hsu et al., 2018).

T-cell subsets appear to differentially segregate in the skin. A large subset of Tregs localizes to HFs (Ali et al., 2017b; Sanchez Rodriguez et al., 2014). Effector and memory CD4⁺ T cells are also commonly observed around the HFs; however, these cells also patrol within the dermis (Collins et al., 2016; Gaylo et al., 2016; Gebhardt et al., 2011). In contrast, CD8⁺ T cells and DETCs preferentially associate with the epidermal basement membrane (BM), although in healthy human skin, a relatively large proportion of CD8⁺ inhabit the epidermis and are capable of migrating back and forth between the dermis and epidermis (Cheuk et al., 2014; Dijkstra et al., 2019; Gebhardt et al., 2011; Thelen and Witherden, 2020). Interstitial motility of skin T cells was presumed to be through integrin-independent amoeboid crawling, as has been described in lymph nodes and for myeloid cells (Gaylo et al., 2016; Jacobelli et al., 2009; Lämmermann et al., 2008; Weninger et al., 2014). However, evidence suggests that at least in the context of inflammation, effector CD4⁺ T cells require integrin αL to move within the dermis (Fernandes et al., 2020; Overstreet et al., 2013). Patrolling T cells use the ECM as a scaffold for interstitial migration, relying on αvβ1 and αvβ3 interactions with fibronectin-decorating collagen fibers (Fernandes et al., 2020; Overstreet et al., 2013). The differences between the motility observed during steady state and inflammation are likely determined by structural remodeling of the ECM (Fernandes et al., 2020; Gaylo et al., 2016; Overstreet et al., 2013; Sorokin, 2010). In this process there is also evidence of subset-driven variation because Th2 differentiation increases αvβ3 expression compared with Th1 cells. Functionally, Th2 cells were observed to patrol a larger area of inflamed dermis than Th1 cells, and manipulation of αvβ3 levels was sufficient to reverse this behavior (Gaylo-Moynihan et al., 2019).

Transit between the dermis and epidermis in healthy skin is likely facilitated by pores in the epidermal BM, although this has not been studied in detail (Oakford et al., 2011). Leukocyte trafficking through such structures is presumably an integrin-independent process owing to their dependency on protrusion-based contractile motility when passing through tight spaces (Jacobelli et al., 2010; Kelley et al., 2014; Lämmermann et al., 2008). Nonetheless, integrin αLβ3 blockade with a mAb against αL (CD49a) markedly reduced the accumulation of T cells in the epidermis of human psoriatic skin xenografts. Treatment with this antibody also mitigated otherwise spontaneous progression of asymptomatic transplants toward pathology, implicating epidermal T cells as mediators of psoriasis (Conrad et al., 2007). However, a more recent study examining αL knockout in murine T-cell responses to Herpes simplex virus infection found no requirement for this integrin in epidermal localization
Instead, $\alpha_1$ supported CD8$^+$ Trm cell persistence in the epidermis, promoted the formation of dendritic protrusions in these cells, and was directly linked to effector function through the induction of IFN-$\gamma$ (Bromley et al., 2020; Cheuk et al., 2017). Given that the original blocking experiments were performed in the context of transplantation and relied on the skin from patients with psoriasis, it is possible that specific inflammatory signals lead to reorganization of the ECM and precipitate a requirement for $\alpha_1\beta_1$ in dermal to epidermal transit. Integrin $\alpha_6\beta_7$ is another adhesion molecule implicated in T-cell function at the epithelium. Induced on T cells by TGF-$\beta$ signaling, $\alpha_6\beta_7$ binds to E-cadherin, which is highly expressed on epithelial cells (Hardenberg et al., 2018; Sivasankar, 2013). Although CD103 ($\alpha_i$) was found to influence DETC dendrite formation, it did not contribute to the cellular morphology of CD8$^+$ Trm cells (Schlickum et al., 2008; Zaid et al., 2017). Trm cells deficient in CD103 demonstrated increased motility within the epidermis, suggesting that this integrin acts to locally restrain (or guide) T-cell migration (Zaid et al., 2017). Consistent with this possibility, deletion of CD103 did not impact the entry of CD8$^+$ Trm cells in the epidermis but was required for their continued persistence at this skin compartment (MacKay et al., 2013).

**Cell–cell interactions.** In addition to mediating motility, adhesion molecules are inextricably linked to T-cell activation and differentiation. LFA-1, VLA-4, and $\alpha_6\beta_7$ are participants in immunological synapse formation and, through engagement with ligands on antigen-presenting or target cells, modulate TCR signaling (Basu and Huse, 2017; Hammer et al., 2019; Hardenberg et al., 2018; Jankowska et al., 2018). This contribution to cell–cell interaction is directly pertinent to CD8$^+$ effector function because either LFA-1 or $\alpha_6\beta_7$ is required for efficient cytotoxicity toward cancer cells (Franciszkiewicz et al. 2013; Le Floch et al., 2007). A B16 melanoma cell line engineered to over-express E-cadherin was more easily eliminated by immune cells, suggesting that the stoichiometry of integrin–cadherin interactions between T cells and their targets regulates effector activity (Sheids et al., 2019). In agreement with these data, culturing CD8$^+$ Trm cells on the $\alpha_1$ ligand, collagen IV, augments IFN-$\gamma$ production (Cheuk et al., 2017). Skin epithelium may also be able to provide T-costimulatory signals by LFA-1. Primary human keratinocyte cultures pretreated with IFN-$\gamma$ were able to activate naïve peripheral blood T cells and induce differentiation toward a Th1 and Th17 phenotype (Orlik et al., 2020). Whereas CD2 ligation is necessary for full T-cell activation, LFA-1 binding to ICAM-1 facilitates cell–cell contact and promotes productive signaling (Orlik et al., 2020; Varga et al., 2010; Verma et al., 2016). Targeting molecular regulators of LFA-1 activation, including its inhibitor MAP4K4 and layilin, has shown potential as a strategy for the treatment of tumors and viral infection (Esen et al., 2020; Mahuron et al., 2020).

**Recirculation.** A large proportion of antigen-experienced skin T cells eventually exit the tissue through draining lymphatics to reenter blood circulation (Bromley et al., 2013; Brown et al., 2010; Collins et al., 2016; Hunter et al., 2016). Even human CD4$^+$CD103$^+$ Trm cells have been identified in circulation, indicating the potential for this population to be mobilized from tissues (Klicznik et al., 2019). T-cell emigration from the skin appears to be at least partially dependent on CCR7/CCL21 and appears to be restrained by S1P signaling (Bromley et al., 2013; Laidlaw et al., 2019; Ledgerwood et al., 2008). Notably, S1P receptor antagonism was found to halt lymphocyte egress by inhibiting migration across lymphatic endothelium in an LFA-1/ICAM-1– and VLA-4/VCAM-1–dependent manner (Ledgerwood et al., 2008). Tregs but not other T cells have been observed to facilitate their own egress by directly promoting the interactions with endothelial VCAM-1 (Brinkman et al., 2016). Presentation of lymphotixin by Tregs to lymphatic endothelial cells induces VCAM-1 expression and is associated with Treg emigration to the draining lymph node (Brinkman et al., 2016; Piao et al., 2018). More recent intravital microscopy experiments revealed that T cells actively crawl through the skin afferent lymphatic capillaries before reaching larger collector vessels. This crawling is dependent on LFA-1 and is modulated by inflammation. Contact hypersensitivity increases T-cell velocity through the upregulation of ICAM-1 on lymphatic endothelial cells. Whereas VLA-4 was dispensable for T-cell movement within the lymphatics, its blockade reduced migration from inflamed skin to the draining lymph node, suggesting a contribution for this integrin to initial lymphatic entry (Teijeira et al., 2017).

**A new horizon in T-cell adhesion.** Although there is increasing evidence pointing to tissue and cellular specificity as a major driver of adhesion dynamics, many of the molecular pathways discussed earlier are broadly conserved across leukocyte lineages. Transformational advances in understanding T-cell function will come through linking cellular behavior to the biochemistry of adhesion molecules dissected in other leukocytes. For example, although we have highlighted several emerging examples of tissue specificity in T-cell migration, there is significantly stronger evidence for this concept in neutrophil tissue recruitment (Margraf et al., 2019). Contributing mechanisms, such as the existence of a $\beta_2$ integrin bent-open headpiece conformation that impairs neutrophil adhesion as well as the reverse transendothelial migratory capability of these cells, have not been deeply examined in T cells (Burn and Alvarez, 2017; Fan et al., 2016; Margraf et al., 2019). In addition, focused efforts to understand T-cell adhesion in the context of their natural three-dimensional environment will be of the highest yield. Advances in intravital microscopy as well as organoid culture systems provide promise toward illuminating human T-cell behavior in the skin.

**Adhesion-based therapeutics in skin disease: promises and challenges**

Because T-cell biology is inextricably linked to cellular adhesion, manipulating these pathways in inflammatory disorders, including in skin diseases, has long been recognized as a compelling therapeutic strategy (Figure 3). However, the fundamental importance and complexity of adhesion biology present an enormous challenge. Designing a drug to target molecules such as integrins requires a deep understanding of molecular mechanisms across multiple
Figure 3. Strategies to target adhesion molecules in disease. Several adhesion molecule inhibitors (both small molecules and mAbs) have been developed to treat inflammatory disorders. To date, efalizumab is the only integrin-blocking therapy to have been approved for use in skin diseases, although it was subsequently withdrawn owing to severe complications. Nonetheless, these drugs illustrate potential opportunities and pitfalls in designing adhesion-based therapeutics. Whereas vedolizumab exhibits exquisite specificity by binding to a conformational epitope unique to the heterodimerization of \( \alpha_4 \) and \( \beta_7 \) integrins, natalizumab and efalizumab encountered problems owing to the promiscuity of their integrin targets (\( \alpha_4 \) and \( \alpha_L \), respectively). Erolizumab, a \( \beta_7 \) integrin–blocking monoclonal in phase III clinical trials for the treatment of IBD may have relevance to skin disease given the importance of \( \alpha_4 \beta_7 \) on skin-resident T cells (Sandborn et al., 2020). One of methotrexate’s proposed mechanisms is the downregulation of selectin and immunoglobulin superfamily molecules expressed on endothelial cells. However, only limited success has been observed with a monoclonal (PF-00547659) targeting MadCAM-1 on mucosal endothelium (Sandborn et al., 2018). IBD, inflammatory bowel disease.

biochemical, states, tissues, and cell types and against a backdrop of intrinsic regulatory layers. Nonetheless, overcoming these difficulties presents an exceptional opportunity for creating highly efficacious precision medicines.

Therapies targeting adhesion pathways are currently approved for the treatment of autoimmune and inflammatory diseases, including multiple sclerosis, Crohn’s disease, and UC (Alsoud et al., 2020; Ley et al., 2016). Predominantly, these approaches rely on a mAb-based blockade of integrin function, although a small molecule LFA-1 antagonist, lifitegrast, is currently approved for dry eye disease (Haber et al., 2019). Vedolizumab, which possesses a safe and effective track record in the treatment of Crohn’s disease and UC (Alsoud et al., 2020; Feagan et al., 2013), provides an illustrative example for the successful development of tissue-specific adhesion–based therapeutics. Vedolizumab binds to a conformational epitope unique to the heterodimerization of human \( \alpha_4 \) and \( \beta_7 \) integrins. This allows precise antagonism of \( \alpha_4 \beta_7 \) interactions with MadCAM-1 on mucosal endothelial cells (Soler et al., 2009). Similar to the role of CLA in skin entry, MadCAM-1 binding mediates the transmigration of T cells across the intestinal mucosa (Fedyk et al., 2012; Soler et al., 2009). Clinical studies and nonhuman primate experiments demonstrate that vedolizumab’s molecular specificity translates into targeted immunomodulation. Healthy subjects and animals treated with vedolizumab exhibited significant loss of \( \beta_7^{+} \) leukocytes from the intestinal tract but not from other tissues (Fedyk et al., 2012; Milch et al., 2013).

Vedolizumab’s success in achieving a tissue-specific response contrasts with that of natalizumab, another approved anti-\( \alpha_4 \beta_7 \) monoclonal. Binding an \( \alpha_4 \) epitope, natalizumab, blocks both \( \alpha_4 \beta_7 \) and \( \alpha_L \beta_1 \) (VLA-1), which is more widely expressed, including on skin-homing T cells (discussed earlier) (Fedyk et al., 2012; Ley et al., 2016). Unfortunately, this comparatively reduced specificity manifests in the potential for developing progressive multifocal leukoencephalopathy (PML), a life-threatening CNS side effect due to reactivation of the polyoma John Cunningham (JC) virus (Cortese et al., 2021; Ley et al., 2016; Milch et al., 2013). Although the exact pathogenesis of this complication remains unclear, blockade of \( \alpha_4 \beta_1 $–VCAM-1 interaction is a likely culprit. JC virus–reactive T cells are important contributors to viral control and disease prevention, but in contrast to vedolizumab, natalizumab treatment is associated with a reduction in CNS T-cell populations (Cortese et al., 2021; Ley et al., 2016; Milch et al., 2013).

Efalizumab, which was briefly approved for treating psoriasis before being removed from the market owing to incidences of PML (complication risk of 1 in 400 compared with that of 1 in 1,000 for natalizumab), illustrates an additional complexity in developing integrin-based drugs (Cortese et al., 2021; Ley et al., 2016). An anti-\( \alpha_4 \) monoclonal, efalizumab, was expected to be highly specific for blocking LFA-1 (\( \alpha_4 \beta_2 \)) because the \( \alpha_4 \) integrin chain only pairs with \( \beta_2 \) (Ley et al., 2016; Mancuso et al., 2020). However, although efalizumab effectively reduces LFA-1 at the T-cell surface, it was also observed to cause the downregulation of \( \alpha_4 \beta_1 \) (Grönholt et al., 2016; Guttman-Yassky et al., 2008; Mancuso et al., 2020). The mechanisms
underlying this response are unclear; however, outside-in signaling through LFA-1 is known to influence α4β1, and crosstalk between these integrins is a feature of their molecular function (Grönholm et al., 2016; Kim and Hammer, 2019; Mancuso et al., 2020). In vitro experiments indicate that efalizumab can induce α4β1, without LFA-1 activation, which is a requirement for integrin crosstalk (Mancuso et al., 2020). Therefore, α4β1 downregulation may occur through additional biochemical interactions.

Although efalizumab ultimately proved disappointing, its effectiveness at reducing cutaneous inflammation is clear. A phase 3 clinical trial testing efalizumab in the treatment of psoriasis found that the majority of patients experienced at least a 50% reduction in lesion severity and area (Lebwohl et al., 2003). Several case reports and small trials have also reported success in using efalizumab to treat hypertrophic lupus erythematosus, lichen planus, and AD (Böhm and Luger, 2007; Navarini et al., 2010; Takiguchi et al., 2007). Follow-up analysis on patients with relapsing psoriasis after cessation of efalizumab observed renewed T-cell and myeloid skin infiltration in skin lesions (Johnson-Huang et al., 2012). In addition to reducing skin homing of pathogenic T-cell clones, efalizumab induces T-cell hyporesponsiveness characterized by attenuated T-cell activation and downregulation of costimulatory and TCR complex molecules (Guttman-Yassky et al., 2008; Kuschei et al., 2011). Together, these findings support the potential for targeting LFA-1–mediated adhesion in skin disease.

An alternative approach to integrin blockade is to target selectins and their ligands. Modulation of selectin interactions required for T-cell entry into the skin may improve selectivity toward inflamed tissue because the expression of selectins and their ligands. Modulation of selectin inmediated adhesion in skin disease.

Adhesion molecules are critical mediators of T-cell accumulation and function in nonlymphoid tissues. These molecules exert functional effects almost continuously as T cells enter and traverse the skin. This breadth of activity means that adhesion mechanisms are highly complex and exhibit multiple layers of regulation and molecular redundancy. Nevertheless, recent research has uncovered several examples of tissue and cell-type specificities, such as between Th1 and Th2 cells or between Tregs and effector T cells. Small variations in how T-cell populations use adhesion molecules to interact with their local environment can result in a large influence on immune response and disease pathology. Because many inflammatory skin disorders have a strong T-cell component, modulating adhesive interactions has long been considered an attractive therapeutic strategy; yet, this approach has most likely not realized its full potential. Despite the current absence of an approved adhesion-targeting therapy for skin diseases, a detailed understanding of relevant molecular pathways has grown significantly since efalizumab was first developed. Developing drugs to target T-cell adhesion presents a formidable challenge in overcoming intrinsic molecular redundancy and functional complexity. The severe off-target complications associated with efalizumab and natalizumab reinforce this difficulty and emphasize a need to comprehensively consider epitope specificity, expression profile, and molecular regulation in designing therapeutics to modulate cellular adhesion. At the same time, doing so opens the possibility for harnessing exquisite biological precision.

ORCIDs
Joshua M. Moreau: http://orcid.org/0000-0002-1227-1508
Victoire Gouirand: http://orcid.org/0000-0002-2566-0061
Michael D. Rosenblum: http://orcid.org/0000-0002-0462-5732

AUTHOR CONTRIBUTIONS
Conceptualization: JM, VG, MDR; Investigation: JM, VG, MDR; Methodology: JM, VG, MDR; Project Administration: JM, VG, MDR; Resources: JM, VG, MDR; Software: JM, VG, MDR; Supervision: MDR; Validation: JMM, VG, MDR; Visualization: JMM, VG, MDR; Writing - Original Draft Preparation: JMM, VG, MDR; Writing - Review and Editing: JMM, VG, MDR

ACKNOWLEDGMENTS
This work was primarily supported by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institute of Health (R01AR070794-01) and DP2-AR068130-01 to MDR. JMM is supported by the Human Frontier Science Program Long-term Fellowship (LT000183/2018-L). Illustrations were created, in part, with BioRender.com.

CONFLICT OF INTEREST
MDR is a consultant and cofounder of Treg Bio., a company focused on regulatory T-cell therapeutics. The remaining authors declare no conflict of interest.

REFERENCES
Abadier M, Pramod AB, McArdele S, Marki A, Fan Z, Gutierrez E, et al. Effector and regulatory T cells roll at high shear stress by inducible tether and sling formation. Cell Rep 2017;21:3885–99.
Ali AJ, Abuelaaf EF, Merzaban JS. An analysis of trafficking receptors shows that CD44 and P-selectin glycoprotein ligand-1 collectively control the migration of activated human T-cells. Front Immunol 2017;8:492.
Cheuk S, Schlums H, Gallais Sére´ zal I, Martini E, Chiang SC, Marquardt N, Bullard DC, Scharffetter-Kochanek K, Mcarthur MJ, Chosay JG, Mcbride ME, Brown MN, Fintushel SR, Lee MH, Jennrich S, Geherin SA, Hay JB, et al. TIM-Biedermann T, Schwa¨ rzler C, Lametschwandtner G, Thoma G, Carballido-Bhushan M, Bleiker TO, Ballsdon AE, Allen MH, Sopwith M, Robinson MK, Angiari S, Donnarumma T, Rossi B, Dusi S, Pietronigro E, Zenaro E, et al. Mechanical communication at the immunological synapse. Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab in vivo.もらって vandalism 1119–1120. Saltarelli A, Fawal, J, M., et al. CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin. Immunity 2017;46:287–98. 42. Naito T, Nakamura Y, et al. Control of alpha4beta7 T cell adhesion in skin. JM Moreau

Bohm M, Luger TA. Lichen planus responding to efalizumab. J Am Acad Dermatol 2007;56(Suppl):S92–3.

Bormowski ML, Hynes RO. Layilin, a novel talin-binding transmembrane protein homologous with C-type lectins, is localized in membrane ruffles. J Cell Biol 1998;143:429–42.

Braun A, Dewert N, Brunnett F, Schnabel V, Hardenberg JH, Richter B, et al. Integrin alpha 4 beta 1 (CD103) is involved in regulatory T-cell function in allergic contact hypersensitivity. J Invest Dermatol 2015;135:2982–91.

Brinkman CC, Iwami D, Hritzo MK, Xiong Y, Ahmad S, Simon T, et al. CD49a regulates cutaneous resident memory CD8+ T cell activation. J Exp Med 2017;114:E2901–11.

Bromley SK, Akbab A, Mani V, Mora-Buch R, Chasse AY, Sama A, et al. CD49a regulates cutaneous resident memory CD8+ T cell persistence and response. Cell Rep 2020;32:108085.

Bromley SK, Yan S, Tomura M, Kanagawa O, Luster AD. Recirculating memory T cells are a unique subset of CD4+ T cells with a distinct phenotype and migratory pattern. J Immunol 2013;190:970–6.

Brown MN, Mintshel SR, Lee MH, Jenmrich S, Heberman SA, Hay JB, et al. Chemoattractant receptors and lymphocyte egress from extralymphoid tissue: changing requirements during the course of inflammation. J Immunol 2010;185:4873–82.

Bullard DC, Scharffetter-Kochanek K, Mccarthur MJ, Chosay JG, Mcbride ME, Montgomery CA, et al. A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. Proc Natl Acad Sci USA 1996;93:2116–21.

Burn T, Alvarez J, Reverse transendothelial cell migration in inflammation: to help or to hinder? Cell Mol Life Sci 2017;74:1871–81.

Capece T, Walling BL, Lim K, Kim KD Do, Bae S, Chung HL, et al. A novel intracelluar pool of LFA-1 is critical for asymmetric CD8+ T cell activation and differentiation. J Cell Biol 2017;216:3817–29.

Cavallaro U, Dejana E. Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol 2011;12:189–97.

Cheuk S, Schlums H, Gallais Séréal J, Martini E, Chiang SC, Marquardt N, et al. CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin. Immunity 2017;46:287–300.

Cheuk S, Wikén M, Blomqvist L, Nylen S, Talmi T, Stälhe M, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol 2014;192:11119–20.
Gaylo A, Schrock DC, Fernandes NRI, Fowell DJ. T cell interstitial migration: motility cues from the inflamed tissue for micro- and macro-positioning. Front Immunol 2016;7:428.

Gaylo-Maynihan A, Prizant H, Popovic M, Fernandes NRI, Anderson CS, Chieu KK, et al. Programming of distinct chemokine-dependent and -independent search strategies for Th1 and Th2 cells optimizes function at inflamed sites. Immunity 2019;51:298–309.e6.

Gebhardt T, Whitney PG, Zaid A, MacKay LK, Brooks AG, Heath WR, et al. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 2011;477:216–9.

Grabbe S, Varga G, Beisset S, Steinitz M, Pendl G, Seeliger S, et al. β2 integrins are required for skin homing of primed T cells but not for priming naive T cells. J Clin Invest 2002;109:183–92.

Grönholm M, Jahan F, Bryushkova EA, Madhavan S, Aguilafloro F, Soto Hinojosa LS, et al. LFA-1 integrin antibodies inhibit leukocyte α4β1-mediated adhesion by intracellular signaling. Blood 2016;128:1270–81.

Guttmann-Yassky E, Vugmeyster Y, Lowes MA, Chamin F, Kikuchi T, Kagen M, et al. Blockade of CD11a by etalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol 2008;128:1182–91.

Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol 2011;5:800–6.

Hammer JA, Wang JC, Saeed M, Pedrosa AT. Origin, organization, dynamics, and function of actin and actomyosin networks at the T cell immunological synapse. Annu Rev Immunol 2019;37:201–24.

Hardenberg JB, Braun A, Schön MP. A Yin and Yang in epithelial immunology: the roles of the α4β1/CD103β7 integrin in T cells. J Invest Dermatol 2018;138:23–31.

Harjupää H, Llott Asens ML, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles in regulation of the immune and tumor microenvironment. Front Immunol 2019;10:1078.

Harrison OJ, Linehan JL, Shih HY, Bouladoux N, Han SJ, Smelkinson M, et al. Commensal-specific T cell plasticity promotes rapid tissue adaptation to injury. Science 2019;363:eaa6280.

Ho AW, Kupper TS. T cells and the skin: from protective immunity to skin diseases. Annu Rev Immunol 2019;37:201–24.

Hunter MC, Teijeira A, Halin C. T cell trafficking through lymphatic vessels. Proc Natl Acad Sci USA 2010;107:7443–8.

Johnson-Huang LM, Pensabene CA, Shah KR, Pierson KC, Kikuchi T, Lentini T, et al. Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs. PLoS One 2012;7:1–9.

Johnston A, Gadjusjon J, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005;114:154–63.

Kalekar LA, Cohen JN, Prevel N, Sandow PM, Mathur AN, Moreau JM, et al. Regulatory T cells in skin are uniquely poised to suppress probiotic immune responses. Sci Immunol 2019;4:eaaw2910.

Kalekar LA, Rosenblum MD. Regulatory T cells in inflammatory skin disease: from mice to humans. Int Immunol 2019;31:457–63.

Kelley LC, Lohmer LL, Hagedorn BJ, Sherwood DR. Traversing the basement membrane in vivo: a diversity of strategies. J Cell Biol 2014;204:291–302.

Kess D, Peters T, Zamek J, Winkenhofer C, Tawadros S, Loser K, et al. CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J Immunol 2003;171:5697–706.

Kim SH, Hammer JA, DA. Intrastromal tollows allows CD4+ T lymphocytes to continue migrating in the upstream direction after flow. Integr Biol (Camb) 2019;11:384–93.

Kliczink MM, Morawski PA, Höllbacher B, Varkhande SR, Motley SJ, Kuri-Cervantes L, et al. Human CD4 + CD103 + cutaneous resident memory T cells are found in the circulation of healthy individuals. Sci Immunol 2019;4:eaaw8995.

Kolev M, West EE, Kunz N, Chaus D, Moreman EA, Rahman J, et al. Diabetes-induced intracellular signaling via LFA-1 facilitates tissue immunity by inducing intrinsic complement C3 expression in immune cells. Immunity 2020;52:127–286.

Kuschei WM, Leitner J, Majdic O, Pickl WF, Zlabinger GJ, Grabmeier-Pisterhammer K, et al. Cosimulatory signals potentiate modulate the T cell inhibitory capacity of the therapeutic CD11a antibody etalizumab. Clin Immunol 2011;139:199–207.

Laidlaw BJ, Gray EE, Zhang Y, Ramírez-Valle F, Cyster JG. Sphinogosine-1-phosphate receptor 2 restrains egress of γδ T cells from the skin. J Exp Med 2019;216:1487–96.

Lämmermann T, Bader BL, Monley SJ, Worbs T, Wedlich-Soldner R, Hirsch K, et al. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 2008;453:51–5.

Lebow M, TYring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, etalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–13.

Lederwood LG, Lal G, Zhang N, Garin A, Essays SJ, Ginhoux F, et al. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral T lymphocytes into alveolar lymphatics. Nat Immunol 2008;9:42–53.

Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol 2004;4:325–35.

Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. Integrin-based therapies: biological basis, clinical use and new drugs. Nat Rev Drug Discov 2016;15:173–83.

Liu J, Chang HW, Huang ZM, Nakamura M, Sekhon S, Ahn R, et al. Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer [e-pub ahead of print]. J Allergy Clin Immunol 2020. https://doi.org/10.1016/j.jaci.2020.11.028 (accessed 24 February 2021).

MacKay LR, Rahimpour MA, Ma JZ, Collins N, Stock AF, Halon ML, et al. The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin. Nat Immunol 2013;14:1294–301.

Mahuron KM, Moreau JM, Glasgow JE, Boda DP, Pauli ML, Gouirand V, et al. Layilin augments integrin activation to promote antitumor immunity. J Exp Med 2020;217:e20130280.

Mancuso RV, Casper J, Schmidt AG, Krähenbühl S, Weitz-Schmidt G. Anti-α4β1 antibodies reveal novel endocytic cross-modulatory functionality. Br J Pharmacol 2019;176:796–711.

Margraf A, Ley K, Zarbock A. Neutrophil recruitment: from model systems to skin gammadelta T cells in wound repair. Science 2002;296:747–50.

Miclea C, Wyant T, Xu J, Parikh A, Kent W, Fox I, et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid Th1lymphocyte immunophenotype. J Neuroimmunol 2013;264:123–6.

Nächter M, Blázquez AB, Shao B, Matesanz A, Prophete C, Berin MC, et al. Physiological contribution of CD44 as a ligand for E-selectin during inflammatory T-cell recruitment. Am J Pathol 2011;178:2437–46.
Nandi A, Estess P, Siegelman M. Bimolecular complex between rolling and firm adhesion receptors required for cell arrest; CD44 association with VLA-4 in T cell extravasation. Immunity 2004;20:453–65.

Navarini AA, Kerl K, French LE, Trueb RM. Control of widespread hypertrophic lupus epithematosus with T-cell-directed biologic etalizumab. Dermatology 2010;220:249–53.

Nosbaum A, Prevel N, Truong HA, Mehta P, Ettinger M, Scharschmidt TC, et al. Cutting Edge: Regulatory T cells facilitate cutaneous wound healing. J Immunol 2016;196:2010–4.

Nuasbaum JC, Van Dyken SJ, von Moltke J, Cheng LE, Mohapatra A, Molosky AB, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 2013;502:245–8.

Oakford ME, Dixon SV, August S, Pickard C, Ardern-Jones M, Lackie P, et al. Migration of immunocytes across the basal membrane in skin: the role of basement membrane pores. J Invest Dermatol 2011;131:1950–3.

Orlik C, Deibel D, Küblbeck J, Balta E, Ganskih S, Habicht J, et al. Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin. Cell Mol Immunol 2020;17:380–94.

Overstreet MG, Gaylo A, Angermann BR, Hughson A, Hyun YM, Lambert K, et al. Regulation of CD11a/CD18 Levels Drive Regulatory T cell Conversion into Th17 Cells in the CD18 hypo PLJ Mice. Mouse Model of Psoriasis. J Immunol 2013;190:2549–53.

Sivasankar S. Tuning the kinetics of cadherin adhesion. J Invest Dermatol 2013;133:2318–23.

Soler D, Chapman T, Yang LL, Wyatt T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha-beta integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864–75.

Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010;10:712–23.

Stummvoll GH, Aringer M, Grisar J, Steiner CW, Smolen JS, Knобler R, et al. Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis 2004;63:569–74.

Sumagin R, Sarelius H. Intercellular adhesion molecule-1 enrichment near tricellular endothelial junctions is preferentially associated with leukocyte transmigration and signals for reorganization of these junctions to accommodate leukocyte passage. J Immunol 2010;184:5242–52.

Sun H, Lagarrigue F, Wang H, Fang Z, Lopez-Ramirez MA, Chang JT, et al. Distinct integrin activation pathways for effector and regulatory T cell trafficking and function. J Exp Med 2021;218:e20201524.

Sun Z, Costell M, Fassler R. Integrin activation by talin, kindlin and mechanical forces. Nat Cell Biol 2019;21:25–31.

Szabo PA, Miron M, Farber DL. Location, location, location: tissue resident memory T cells in mice and humans. Sci Immunol 2019;4:1–12.

Takiguchi R, Tötte S, Simpson B, Harper E, Blauvelt A, Hanфин J, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007;56:222–7.

Teijeira A, Hunter MC, Russo E, Proulx ST, Frei T, Debes GF, et al. T cell migration from inflamed skin to draining lymph nodes requires intramympathic crowding supported by ICAM-1/LFA-1 interactions. Cell Rep 2017;18:857–65.

Thelen F, Witherden DA. Get in touch with dendritic epithelial T cells! Front Immunol 2020;11:1656.

Varga G, Nippe N, Balkow S, Peters T, Wild MK, Seeliger S, et al. LFA-1 contributes to signal i of T-cell activation and to the production of T-helper 1 cytokines. J Invest Dermatol 2010;130:1005–12.

Verma NK, Fazil MHUT, Ong ST, Chalasani MLS, Low JH, Kottaiswamy A, et al. LFA-1/ICAM-1 ligation in human T cells promotes Th1 polarization through a GSK3β signaling–dependent notch pathway. J Immunol 2016;197:108–18.

Wang H, Peters T, Sindrilaru A, Kess D, Oreshkova T, Yu XZ, et al. TGF-β-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis. J Clin Invest 2008;118:2629–39.

Wang Y, Shen Y, Xiao YF, Wang Q, Kanekura T, Li Y, et al. Hypomethylation and overexpression of ITGAL (CD11a) in CD4(+) T cells in systemic sclerosis. Clin Epigenetics 2014;6:25.

Weninger W, Biro M, Jain R. Leukocyte migration in the interstitial space of skin: the role of basement membrane pores. J Invest Dermatol 2007;129:1–9.

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/